vimarsana.com

Latest Breaking News On - Canagliflozin invokana - Page 1 : vimarsana.com

Certain Type 2 Diabetes Drugs Lower Risk of Kidney Stones

Patients with type 2 diabetes treated with SGLT2 inhibitors vs other common diabetes drugs show up to a 31% reduced risk of kidney stone development.

Canagliflozin-invokana
Bexagliflozin-brenzavvy
Dapagliflozin-farxiga
Empagliflozin-jardiance

Europe Approves Empagliflozin for Chronic Kidney Disease

The SGLT2 inhibitor empagliflozin (Jardiance) was approved by European regulators for treating adults with chronic kidney disease. The FDA is reviewing a new drug application for this indication.

Dapagliflozin-farxiga
Canagliflozin-invokana
Boehringer-ingelheim
Janssen-pharmaceuticals
Astrazeneca
European-commission
European-union
Drug-administration
Obesity-global-medical-affairs
Kidney-protection-with-empagliflozin
Leonard-glass
Dapagliflozin-also-approved

diabetes, Schema-Root news

Cross-linked news, and information resources about diabetes

United-states
New-york
Arkansas
Georgia
Middletown
Illinois
Texas
University-of-illinois-at-chicago
Philadelphia
Pennsylvania
Edinburg
Delaware

vimarsana © 2020. All Rights Reserved.